Harmony’s ZYN002 Is Latest Drug To Flunk In Fragile X Syndrome

 
• By Alaric DeArment
  
Harmony announced the failure of the Phase III RECONNECT trial of ZYN002 in fragile X syndrome. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D